Role of autophagy-related protein expression in patients with rectal cancer treated with neoadjuvant...

Area of Science:

• Oncology
• Cellular Biology
• Cancer Therapeutics

Background:

• Autophagy plays a dual role in cancer, influencing tumor development and treatment resistance.
• Understanding autophagy's role in rectal cancer is crucial for improving patient outcomes.
• Neoadjuvant chemoradiotherapy is a standard treatment for rectal cancer, but resistance remains a challenge.

Purpose of the Study:

• To investigate the expression levels of autophagy-related proteins, specifically LC3β and beclin-1, in rectal cancer patients.
• To assess the association between these protein expression levels and clinicopathological parameters.
• To evaluate the clinical significance of autophagy-related proteins in the context of neoadjuvant chemoradiotherapy response and patient survival.

Main Methods:

• Immunohistochemistry was used to quantify the expression of LC3β and beclin-1 in 101 rectal cancer patient specimens.
• Data were analyzed for associations with clinicopathological features and survival outcomes.
• Multivariate analysis was performed to determine prognostic significance.

Main Results:

• High expression of beclin-1 was observed in 31.7% of patients, and high LC3β expression in 46.5%.
• Increased LC3β expression and altered autophagy-related protein expression were inversely associated with pathologic complete response (p=0.003 and p=0.046, respectively).
• Autophagy-related protein expression did not significantly predict relapse-free or overall survival in multivariate analysis.

Conclusions:

• Elevated expression of autophagy-related proteins is strongly associated with reduced efficacy of neoadjuvant chemoradiotherapy in rectal cancer.
• Autophagy represents a promising therapeutic target to enhance the effectiveness of neoadjuvant chemoradiotherapy for rectal cancer.
• Further research into modulating autophagy pathways could lead to improved treatment strategies.